Save The Date: October 24-25, 2018
10 on the Park, New York City

2016 Agenda


Wednesday, November 2, 2016

7:45am-5:30pm Registration
8:00am-8:45am Pipeline Café
8:45am Welcoming Remarks

Opening Plenary Session: How Investors And Strategics Evaluate Early Stage Opportunities
Investors and strategics consider opportunities through a different lens than company management at every stage. What do early stage companies need to understand about how they may be valued and what can they do to increase value.

Moderator: Ellen B. Corenswet, Partner, Covington & Burling LLP

  • Marian T. Nakada, PhD, Vice President Venture Investments, Johnson & Johnson Innovation – JJDC Inc.
  • Art Pappas, MBA, Managing Partner, Pappas Ventures
  • Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital LLC
  • Bavani Shankar, MBA, Senior Director, Business Development, Scientific Partnering & Alliances, AstraZeneca

Human Microbiome: Exploring the Promise of the Enteric Environment

As we endeavor to unlock the mystery of the human microbiome, we draw closer to the root of many illnesses. This year, the White House launched the National Microbiome Initiative, bringing even more attention to this expanding area. Companies are racing to explore ways to manipulate the trillions of symbiotic microbes in our ‘enteric nervous system’ in order to fight a wide range of afflictions – from modifying the microbial environment to developing genetically engineered bacteria. Roughly two-thirds of the body’s immune system is located in the gut and the microbiome is integral the body’s ability to protect itself from infectious diseases, autoimmune disorders and inflammatory diseases, heart disease, asthma and infections of the lungs, among other illnesses. Studies of the gut-brain axis have also shown that neurological disorders, such as Parkinson’s and Alzheimer’s disease, MS, autism, depression and anxiety are strongly connected to changes of the microbiome. Experts in the human microbiome will provide insights and discuss the enormous challenges and possibilities associated with this exciting field.

Moderator: Keith A. Bostian, PhD, Chief Executive Officer, Institute for Life Science Entrepreneurship (ILSE)

  • Dario A. Gutierrez, PhD, Immuno-biology Lead, Merck Research Labs- Cambridge Exploratory Science Center
  • Bernat Olle, PhD, Co-Founder, Chief Executive Officer, Vedanta Biosciences
  • Kathryn Stein, PhD, Principal, Kathryn Stein Consulting (Former Director, Division of Monoclonal Antibodies, FDA)
  • Geoffrey von Maltzahn, PhD, Partner, Flagship VentureLabs

Emerging Company Showcase  – Medical Device Forum 

10:00am – MicroVide, LLC
10:15am – Kestrel Labs, Inc
10:30am – Perceptive Navigation
10:45am – Coridea, LLC


Partnering Forum


Business Workshop: Building Strategic Collaborations
Why you should be talking to partners and how partners can help advance your asset/discovery at an early stage through collaboration.

Moderator: Kimberly Ha, Senior Director, FTI Consulting

  • Jarrod Borkat, MBA, Senior Director, Head of External Collaborations and Government Contracts, MedImmune, LLC
  • Cláudia Hirawat, Independent BD Consultant & Advisor
  • Tingting Zhang-Kharas, PhD, Advisor – Oncology External Innovation, Eli Lilly and Company

Emerging Company Showcase

11:00am – Zumbro Discovery, Inc. 
11:15am – Aperiomics
11:30am – Angiocrine Bioscience
11:45am – 3PrimeDx, Inc.

12:00pm-1:05pm Lunch with The Experts
12:00pm-1:05pm Pipeline Café

Immuno-Oncology: Cracking the Code of Personalized Medicine
Immuno-oncology therapies continue to revolutionize treatment for some of the most difficult to treat cancers including metastatic kidney cancer, metastatic melanoma, and lung cancer, among others. Sustainable results with a significantly extended survival duration has become a realistic expectation for a growing fraction of patients. Immuno-therapies show even greater promise when combined with each other, or with conventional or targeted therapies. And yet not all patients respond equally, and some don’t respond at all. How can doctors predict which therapies will be effective for which patients? This panel will explore current efforts in the development of new immuno-therapies and companion diagnostics, and the role that “big data” will play in helping researchers and clinicians select and combine the best possible therapies in clinically relevant time frames.

Moderator: Todd Haim, PhD, Program Director, SBIR Development Center, National Cancer Institute, National Institutes of Health

  • Jeffrey M. Bockman, PhD, Vice President, Defined Health
  • Kenneth Emancipator, MD, Executive Medical Director and Head, Companion Diagnostics, Merck Research Laboratories
  • William G Hearl, PhD, Chief Executive Officer, Immunomic Therapeutics, Inc.
  • Anton Xavier, MS, MBA, NY/NYC Biotech Scout, Targeted Therapeutics Discovery, Pfizer WRD

Emerging Company Showcase

1:15pm – Symbiotic Health
1:30pm – Platelet BioGenesis, Inc.
1:45pm – Navigen, Inc.
2:00pm – Savonix


Partnering Forum


Emerging Company Showcase 

Tower Room 
2:15pm – TargaGenix
2:30pm – Intensity Therapeutics
2:45pm – Countervail Corporation
3:00pm – AboGen
3:15pm – Shuttle Pharmaceuticals


Emerging Company Showcase 

Columbus Room
2:15pm – ZATA Pharmaceuticals, Inc.
2:30pm – Indalo Therapeutics
2:45pm – Biosortia Pharmaceuticals
3:00pm – Actinobac Biomed, Inc.
3:15pm – NovoMedix, LLC


Business Workshop: Company Building
In order to grow and succeed, a company needs the right structure, controls, financing and team. Learn how to build your organization as you grow to limit risks and pave the road for success.

Moderator: Joseph V. Gulfo, MD, MBA, Executive Director of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University.

  • Laurence Blumberg, MD, Founder & Chief Operating Officer, Syntimmune, Inc.
  • Stephanie Fertig, MBA, Director, NINDS Small Business Programs, National Institute of Neurological Disorders and Stroke, National Institutes of Health
  • Anna Kazanchyan, MD, Founder & CEO, Saghmos Therapeutics Inc.
  • Kristen Kosofsky, Sr. Managing Director, Hercules Technology Capital
  • Steven Kreit, Partner, EisnerAmper

Emerging Company Showcase 

3:30pm – Pulmokine, Inc.
3:45pm – Mebias Discovery LLC
4:00pm – PreventAGE Health Care LLC
4:15pm – Pulmotect, Inc.


Plenary Session: Working With The Big Biopharmas
Big Biopharmas are increasingly looking to early stage biotechs for innovative products to fill their pipelines. What are these companies looking for, and how can you get on their radar screen?

Moderator: Dennis J. Purcell, Founder and Senior Advisor, Aisling Capital LLC

  • Karen Akinsanya, PhD, Associate Vice President, Head, Early Stage Scientific Assessment, Merck
  • Ellen Lubman, MBA, Vice President, External Science & Innovation, Allergan PLC
  • Nouhad Husseini, MBA, Senior Director, Business Development, Regeneron Pharmaceuticals
  • Ron Newbold, MS, MBA, PhD, Vice President, External R&D Innovation – Head Global Scouting, Pfizer
5:30pm-7:00pm Reception & Pipeline Café

Thursday, November 3, 2016

8:00am-3:00pm Registration
8:15am-9:00am Pipeline Café

Plenary Session: The Early Stage Funding Ecosystem
Funding options for early-stage companies have expanded to include much more than venture capital. Our panel will discuss the various options for early-stage funding as well as the pros and cons of different alternatives and where companies need to look for funding today.

Moderator: Mark Simon, MBA, Partner, Torreya Partnerss

  • Stuart Jacobowitz, Director of Business Development, FreeMind Group
  • Kevin Koch, PhD, Venture Partner, OrbiMed
  • Bill Podd, President, Landmark Angels and Landmark Family Office
  • Barbara S. Schilberg, Managing Director and Chief Executive Officer, BioAdvance
  • Alex Zisson, Managing Director, H.I.G. Capital

Regenerative Medicine: Will iPS Cells Deliver As Promised?
Stem cell therapy makes up the largest part of the regenerative medicine market – with hundreds of clinical trials around the world. Researchers are endeavoring to restore brain function in patients suffering from neurodegenerative diseases via stem cell transplants of induced pluripotent stem (iPS) cells harvested from the patient’s own skin. Using cells from the patient reduces the risk of the body rejecting the transplant. Like embryonic stem cells – but without the ethical issues that came along with them – iPS cells are able to create any cell in a body by a process called differentiation. But to persuade iPS cells into the required cell type, scientists have to create an ideal environment and combination of molecules to add to the stem cells in order to properly support differentiation. These iPS cells are being developed into replacement neurons, engineered into healthy brain tissue and as replacement muscle for a damaged heart, but time will tell if these transplant options will be completely safe and as effective as is hoped. Join our panel of experts as they discuss the most recent improvements and future possibilities in this field.

Moderator: Stephen Chang, MD, Senior Vice President for Strategic Initiatives, The New York Stem Cell Foundation

  • Hina W. Chaudhry, MD, Associate Professor of Medicine, Director, Cardiovascular Regenerative Medicine, Mount Sinai School of Medicine
  • Stefan Irion, MD, Program Manager, New York State Stem Cell Science Consortia, Memorial Sloan Kettering Cancer Center
  • Douglas W. Losordo, MD, FACC, FAHA, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer, Caladrius Biosciences
  • Stephen H. Tsang, MD, PhD, Associate Professor in Pathology & Cell Biology, László Bitó Associate Professor in Ophthalmology, Columbia University

Emerging Company Showcase – Medical Device Forum 

10:00am – SFC Fluidics Inc.
10:15am – Theragnostic Technologies
10:30am – Imbio, LLC
10:45am – Garwood Medical Devices. LLC


Partnering Forum


Business Workshop: Prioritize Communication
Early stage companies often neglect developing this critical toolbox allowing them to tell their story externally to investors, media, and potential partners as well as internally, to their team and stakeholders. Building a solid communication program that supports each stage of development and strategic objectives is an essential task for companies large and small.

Moderator: Gregory Q. Tiberend, President & Chief Executive Officer, Tiberend Strategic Advisors, Inc

  • Kate de Santis, Vice President of Investor Relations Iroko Pharmaceuticals, LLC
  • Jen LaVin, MBA, Principal, SMP Communications
  • Felicia Vonella, Executive Director, Investor Relations & Corporate Communications, Acorda Therapeutics

Emerging Company Showcase 

11:00am – ProLungDx
11:15am – Azevan Pharmaceuticals
11:30am – Aegle Therapeutics
11:45am – NĒRx Biosciences

12:00pm-1:05pm Lunch with The Experts
12:00pm-1:05pm Pipeline Café

Strategic Partner Presentations

  • National Institutes of Health
  • AstraZeneca/MedImmune
  • Eli Lilly and Company
  • Merck

Emerging Company Showcase 

1:15pm – iCell Gene Therapeutics
1:30pm – Aronora, Inc
1:45pm – NeuroSigma
2:00pm – Immunophotonics


Partnering Forum


Emerging Company Showcase 

Tower Room: 
2:15pm – Synactix Pharmaceuticals
2:30pm – KAER Biotherapeutics
2:45pm – OptiKira
3:00pm – NuvOx Pharma

Columbus Room 
2:15pm – ReoLab
2:30pm – BiologicsMD, Inc. 
2:45pm- AAVet Therapeutics
3:00pm –  VentriNova
3:15pm – WRS Therapeutics


Business Workshop: IP and Contracts
Solid IP is the foundation each and every asset needs to attract funding and potential partners. Thorough and well thought-out contracts put a company in a position where it can capitalize on its IP and advance.

Moderator: Brian P. O’Shaughnessy, Shareholder, RatnerPrestia; President-elect, Licensing Executives Society (LES) (USA & Canada)

  • Peter DeLuca, MS, Partner, Carter, DeLuca, Farrell & Schmidt, LLP
  • Thomas Gallagher, Principal, Fenagh Group
  • Edwin H. Gordon, MBA, Co-Head of Healthcare Investment Banking, Ladenburg Thalmann
  • Dov Hass, Director, Transactions and Corporate Law, Regeneron Pharmaceuticals

Emerging Company Showcase 

3:30pm – Allosteros Therapeutics 
3:45pm – HDL Apomics
4:00pm – PIN Pharma, Inc. 
4:15pm – Traverse Biosciences


Closing Plenary Session & Reception: The Political Impact Of The Election: How The Results Will Impact Our Industry
Every national election brings a climate of uncertainty for the biopharmaceutical sector. But this election, the industry faces more storm clouds than usual. From promises to repeal the Affordable Care Act on one hand or to expand it to a true single payer system on the other and populist urges to control prescription drug costs at play in both major parties, the 2016 presidential election promises nothing if not a potential sea change. What can we expect from a new administration and how will it impact the industry¹s key regulatory agencies and federal support for research?

Moderator: Wade Ackerman, Partner, Covington & Burling LLP

  • Eleanor “Ellie” Dehoney, Vice President, Policy and Advocacy, Research!America
  • Paul Howard, Senior Fellow, Director, Health Policy, Manhattan Institute
  • Joan L. Kutcher, of Counsel, Covington & Burling LLP